Jump to content

Carol Jennings

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Qcne (talk | contribs) at 19:37, 13 September 2023 (Minor copyedits). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This sandbox is in the article namespace. Either move this page into your userspace, or remove the {{User sandbox}} template.

Carol Jennings
Born
Carol Bexon

(1954-03-25) March 25, 1954 (age 70)
Nottingham, England
NationalityBritish
Years active1986-present
Known forAlzheimer's Disease activism

Carol Joyce Jennings (née Bexon; born 25 March 1954) is a British campaigner and advocate for research into Alzheimer's Disease. As of 2023 she serves as an honorary Vice-President of the Alzheimer's Society[1]. Through her activism in the 1980s, Jennings brought her family to the attention of researchers studying the disease, which subsequently led to the discovery of the London Mutation[2][3]. This mutation, found on the Amyloid Precursor Protein (APP) gene located on chromosome 21, marked a significant breakthrough in understanding the genetic basis of Alzheimer's Disease[1] and provided evidence for the development of the 'amyloid hypothesis', which attempts to explain the underlying causes of Alzheimer's Disease[1][4].

Early life and biography

Jennings was born in Nottingham, England, to Joyce and Walter Bexon. She received her education at Bilborough Grammar School and later attended Chester College, where she completed her teacher training. She went on to marry Stuart Jennings, a Methodist minister and historian, and they had two children[5][6]. It was during this period that her father, Walter, in his mid-50s at the time, began to exhibit symptoms of Alzheimer's Disease[7].

Discovery of the London Mutation

By the mid-1980s, three of Walter's siblings also displayed signs of Alzheimer's Disease, with symptoms emerging much earlier than expected—in their 40s and 50s. Convinced that there must be a genetic link and determined to find answers, Jennings wrote a letter to the research team led by John Hardy in the spring of 1986[8]. At that time, Hardy was an Assistant Professor of Biochemistry at St. Mary's Hospital, Imperial College London[3].

Genetic Alzheimer’s is rare, accounting for only about 1% of Alzheimer’s cases, but Hardy believed that Jennings’s family could provide clues to the cause of the condition in the wider population, known as 'sporadic Alzheimer’s Disease[4].'

Intrigued by the possibility, Professor Hardy and his team collected blood samples from the Jennings family to compare the genetic differences between those who developed Alzheimer's and those who did not. The search took about five years. From the blood samples, DNA was extracted, and Hardy’s team used the Southern Blotting technique to examine the genes on chromosome 21. This chromosome was chosen because individuals with three copies of chromosome 21 (Down Syndrome) all develop Alzheimer’s Disease[9].

The breakthrough came in 1991. Alison Goate, a junior researcher on the team, discovered a specific gene mutation responsible for the disease in Jennings’s family. Goate, now a professor at Icahn School of Medicine at Mount Sinai, NY, later recalled the discovery as a "eureka moment."[8] The research findings were published in Nature on 21 February 1991[10], with a summary reported in the British press on 16 February[11][12][13].

The mutation, known as the 'London mutation,' affects the amyloid precursor protein (APP) gene, leading to the formation of amyloid plaques in the brain during Alzheimer's Disease. Amyloid disrupts normal brain processes by overactivating brain cells and causing ongoing inflammation. It can also impact blood flow and involve other proteins in the brain. When excessive amyloid accumulates, it can interact with the toxic protein tau, causing neuronal death. In those with genetic Alzheimer’s, this process occurs early because the patient produces too much APP. However, the same process also happens in those with non-genetic Alzheimer’s, albeit at a slower rate[9].

In 1992, as a direct result of the discovery of mutations in the APP gene, Professor Hardy and Professor David Allsop published the amyloid cascade hypothesis. They hoped that this hypothesis would help in designing drugs to intervene in the disease's progression, influencing the direction of Alzheimer’s research for the following three decades[4].

Later developments and recognition

After the discovery of the London mutation, Jennings left her teaching career to work in Alzheimer’s advocacy full-time. Initially, she served as the Alzheimer's Society’s first Coordinator for Younger People with Dementia and later worked with smaller dementia charities while also functioning as an independent advocate for dementia caregivers[14].

As the amyloid cascade hypothesis gained momentum, Professor Hardy received recognition for his contributions to the field. In 2015, Hardy became the UK’s first recipient of the Breakthrough Prize in Life Sciences for "discovering mutations in the amyloid precursor protein (APP) gene that cause early-onset Alzheimer’s Disease, linking the accumulation of APP-derived beta-amyloid peptide to Alzheimer’s pathogenesis, and inspiring new strategies for disease prevention." In his acceptance speech for this award, he expressed special gratitude to Jennings’s family. In 2018, Hardy, alongside Christian Haass, Bart De Strooper and Michel Goedert, was honoured with the Brain Prize for "ground-breaking research on the genetic and molecular basis of Alzheimer’s Disease."[15]

Over time, researchers have expanded upon and challenged this hypothesis, but developing drugs that target amyloid proteins has proven to be a significant challenge, with many failures, underwhelming results, and dangerous side effects reported[16].

When Jennings herself began to develop symptoms of Alzheimer's Disease in 2008, she took a step back from her speaking and advocacy work[17]. However, with the development of new and successful anti-amyloid treatments, journalists and researchers rekindled their interest in the origins of the amyloid hypothesis and Carol Jennings's involvement.

One such success was shown in a large-scale trial of the monoclonal antibody treatment lecanemab. Professor Hardy described the outcome as both "modest" and "historic," and hailed it as the beginning of the end for Alzheimer's Disease. In particular, there is hope that anti-amyloid therapies could eventually be used to prevent the disease ever progressing to the symptomatic stage[18]. This resulted in renewed press interest in the Jennings family, and their contribution was once again covered by the press[19].

In 2022, the BBC announced its commissioning of a 90-minute feature documentary, recounting the story of the Jennings family and their ongoing involvement in Alzheimer's research, set to be broadcast on BBC Two and BBC iPlayer[20][21].

In 2023, both Carol and Stuart Jennings were appointed honorary Vice-Presidents of the Alzheimer's Society, acknowledging their "extraordinary contribution to the field of dementia research."[1][22]

See Also

References

Citations

  1. ^ a b c d "Honouring a couple affected by dementia for their contributions to dementia research". Alzheimer's Society. Retrieved 12 September 2023.
  2. ^ "APP V717I (London)". Alzheimer Research Forum. Retrieved 12 September 2023.
  3. ^ a b HIH.gov Archived 5 November 2011 at the Wayback Machine
  4. ^ a b c "Feature: The 'historic' Alzheimer's breakthrough that is 30 years in the making". University College London. Retrieved 12 September 2023.
  5. ^ Zhang, Gary (30 July 2017). "Three generations of a British family are helping the fight against Alzheimer's". i (newspaper). Retrieved 13 September 2023.
  6. ^ Scougall, Murray (5 December 2016). "Rare hereditary form of dementia casts shadow over family". The Sunday Post. Retrieved 13 September 2023.
  7. ^ "Carol's story: dementia in the family". FutureLearn. Retrieved 12 September 2023.
  8. ^ a b "A Eureka Moment: Carol's Story". University College London. Retrieved 12 September 2023.
  9. ^ a b Wiseman, Frances K.; Al-Janabi, Tamara; Hardy, John; Karmiloff-Smith, Annette; Nizetic, Dean; Tybulewicz, Victor L. J.; Fisher, Elizabeth M. C.; Strydom, André (September 2015). "A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome". Nature Reviews Neuroscience. 16 (9): 564–574. doi:10.1038/nrn3983. PMID 26243569.
  10. ^ Goate, Alison; Chartier-Harlin, Marie-Christine; Mullan, Mike; Brown, Jeremy; Fidani, Liana; Giuffra, Luis; Haynes, Andrew; Irving, Nick; James, Louise; Mant, Rebecca; Newton, Phillippa; Rooke, Karen; Roques, Penelope; Talbot, Chris; Pericak-Vance, Margaret; Roses, Alien; Williamson, Robert; Rossor, Martin; Owen, Mike; Hardy, John (21 February 1991). "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease". Nature (349): 704–706. doi:10.1038/349704a0. Retrieved 12 September 2023.
  11. ^ Mihill, Chris (16 February 1991). "Defective gene link to dementia disease". The Guardian.
  12. ^ Highfield, Roger (16 February 1991). "British first to find a cause of Alzheimer's". The Daily Telegraph.
  13. ^ Prentice, Thomson (16 February 1991). "Family link leads to breakthrough on Alzheimer's Disease". The Times.
  14. ^ "Services for younger people with Alzheimer's disease and other dementias" (PDF). Royal College of Psychiatrists. Retrieved 13 September 2023.
  15. ^ "Alzheimer's Disease - The Lundbeck Foundation". Lundbeck Fonden. Retrieved 12 September 2023.
  16. ^ Vogt, Anne-Cathrine S.; Jennings, Gary T.; Mohsen, Mona O.; Vogel, Monique; Bachmann, Martin F. (15 February 2023). "Alzheimer's Disease: A Brief History of Immunotherapies Targeting Amyloid β". International Journal of Molecular Sciences. 24 (4): 3895. doi:10.3390/ijms24043895. PMID 36835301. Retrieved 13 September 2023.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  17. ^ Yedroudj, Latifa (8 April 2023). "The Coventry woman who became a pioneer in Alzheimer's research". Coventry Telegraph. Retrieved 13 September 2023.
  18. ^ Abbott, Alison (16 June 2022). "Treating Alzheimer's Before It Takes Hold". Scientific American. Retrieved 13 September 2023.
  19. ^ Whipple, Tom (18 June 2021). "Has this man found the key to the Alzheimer's time bomb?". The Times. Retrieved 13 September 2023.
  20. ^ "BBC announces new documentaries at Sheffield Doc/ Fest 2022". BBC. Retrieved 12 September 2023.
  21. ^ "Family 23: BBC Two Announce new intimate family documentary". TV Zone UK. Retrieved 12 September 2023.
  22. ^ "Carol and Stuart Jennings – Vice Presidents at Alzheimer's Society". Alzheimer's Society. Retrieved 12 September 2023.

Works cited

  • Armstrong, Sue (2019). Borrowed time: The Science of How and Why We Age. London: Bloomsbury Sigma. ISBN 978-1-4729-3606-6.
  • Jebelli, Joseph (2017). In Pursuit of Memory: The Fight Against Alzheimer's. London: John Murray. ISBN 978-1-473-63576-0.


Category:Alumni of the University of Chester Category:1954 births Category:Living people Category:People from Nottingham Category:Alzheimer's disease activists Category:People with Alzheimer's disease

Retrieved from "https://en.wikipedia.org/w/index.php?title=Carol_Jennings&oldid=1175255583"